Ask about this productRelated genes to: BCL6 antibody
- Gene:
- BCL6 NIH gene
- Name:
- BCL6 transcription repressor
- Previous symbol:
- ZNF51
- Synonyms:
- ZBTB27, LAZ3, BCL5, BCL6A
- Chromosome:
- 3q27.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-04-12
- Date modifiied:
- 2019-01-25
Related products to: BCL6 antibody
Related articles to: BCL6 antibody
- : is an important bacterial pathogen in crucian carp and can cause serious disease outbreaks and substantial economic losses in aquaculture. : To evaluate how infection and its inactivated vaccine modulate immune responses in . : 270 juveniles were allocated into three groups: a saline-injected control group (Ctrl), a vaccination group receiving an inactivated vaccine (Vac), and an artificial infection group (AIG) subjected to stimulation. Liver, spleen, head kidney, gill, and intestine samples were collected from fish after anesthesia. The relative transcript levels of , , , , , , , and were quantified. For liver transcriptome analysis, the effective library concentration was determined. And the 16S rRNA gene resulting reads of fish gill symbiotic microbiota were processed for downstream bioinformatic analysis. : The results showed that the Vac achieved an RPS of 73.33%, and vaccination significantly upregulated multiple immune-related genes in different fish organs. With transcription across organs emerging as a robust sentinel readout. The Pearson correlation coefficient () of BAFF between other genes were all ≥0.8. GO and KEGG enrichment analyses indicated that AIG had more DEGs than Vac (5885 vs. 4008) and Ctrl (6910 vs. 6178), respectively. Some genes in AIG revealed significant over-representation of immune pathways, such as , , and . The fish gill microbiota comprised a diverse set of low-abundance taxa, the phylum level was dominated by Proteobacteria and Fusobacteriota across all groups; whereas, the Vac group remained broadly closer to the Ctrl group in overall composition. : These results indicated marked post-challenge immune-metabolic coupling in the liver, and suggested coordinated immunophysiological interplay between the liver and the spleen. Gill microecology of symbiotic bacteria was affected by vaccination or challenge reactions, which in turn affects the health of the gills or the organism itself. - Source: PubMed
Publication date: 2026/03/29
Wang JunboHuang ShiyongLai YingtiaoWang PingWang FeifeiPan DahuiZhao FeiGong Hua - T helper (Th) and T follicular helper (Tfh) cells support cellular and humoral immunity, respectively. How activated CD4 T cells commit to these fates remains unclear. Using a mouse vaccination model, we traced endogenous, polyclonal CD4 T cells during bifurcation into Th1 and Tfh lineages. We found that Th1 and Tfh cells originate from shared, highly proliferative TCF1SLAMF6PD-1 precursor clones that co-express Th1- and Tfh-related transcription factors and chemokine receptors, including T-bet, BCL6, CXCR3, and CXCR5. The generation of common Th1/Tfh precursors from naive CD4 T cells requires CD28 costimulation but occurs independently of CD40, ICOS, and interaction with type 1 conventional dendritic cells (cDC1s) or B cells. Lineage commitment subsequently diverges: differentiation into Th1 cells relies on CD40 costimulation and cDC1s, whereas differentiation into Tfh cells requires ICOS costimulation and B cells. Activated CD4 T cells thus give rise to a common Th1/Tfh precursor whose fate depends on interactions with distinct antigen-presenting cells. - Source: PubMed
Publication date: 2026/04/21
Bosma Douwe M TBusselaar JuliaStaal Mo Dde Koning MylèneReljić MirnaLei Xinde Wit TomXiao YanlingBorst JannieSalerno Fiamma - Mantle cell lymphoma (MCL) is a rare, aggressive subtype of B-cell non-Hodgkin lymphoma with rare cutaneous involvement that typically indicates advanced systemic disease. We report a case of indolent MCL in a 56-year-old previously healthy male who presented with a 5-year history of edematous, painful plaques and associated onychodystrophy in the bilateral toes. Histopathology demonstrated a multinodular dermal and subcutaneous infiltrate of atypical lymphocytes. Immunohistochemistry revealed a primary B-cell population diffusely positive for CD20 and BCL2 and focally positive for BCL1. These cells were negative for CD5, SOX-11, BCL6, and LEF1. In situ hybridization demonstrated admixed lambda-restricted plasma cells, indicating plasmacytic differentiation. Fluorescence in situ hybridization testing for an IGH/CCND1 translocation was positive, confirming a diagnosis of MCL. While bone marrow biopsy demonstrated 10%-20% involvement by MCL, staging revealed no lymphadenopathy or visceral disease. No significant peripheral blood laboratory abnormality was noted. To our knowledge, this is the first reported case of cutaneous involvement by MCL confined to the bilateral toes. This case is also notable for its absence of typical markers, namely CD5 and SOX-11, plasmacytic differentiation, and indolent clinical behavior. We discuss the diagnostic and clinical significance of these atypical clinicopathologic features and diagnostic overlap with other cutaneous B-cell lymphomas, emphasizing the importance of comprehensive immunophenotypic and molecular evaluation in atypical presentations. - Source: PubMed
Publication date: 2026/04/23
Sun Q WiltonCruz Sebastian AMenke JoshuaTan BrentRieger Kerri EBulterys Philip L - Cases of diffuse large B-cell lymphoma (DLBCL) of the uterus co-expressing CD5 are exceedingly rare and diagnostically challenging due to its nonspecific clinical and radiological features, which often mimic other uterine malignancies. This study retrospectively analyzes the cytopathological and histopathological characteristics of this entity in uterine cavity drainage fluid to facilitate its recognition. - Source: PubMed
Publication date: 2026/04/07
Yu QinlingFu ChaojuJing FengZeng Ying - Hans' algorithm (HA) is the most frequently used surrogate biomarker scheme for subtyping Diffuse large B-cell lymphoma (DLBCL) by the cell-of-origin (COO) into GCB and non-GCB subtypes. The originally published positive and negative predictive value (PPV and NPV) against gene expression profiling (GEP) subtypes were less than perfect and were not fully reproducible in published literature. Furthermore, little is known about how the HA performs in clinical practice. The Canadian Association of Pathologists National Standard Committee for High Complexity Testing (CAP-ACP NSCHCT) initiated a Canada-wide project to assess the current diagnostic accuracy of the HA in clinical practice, harmonize the analytical phase of the IHC assays used for HA, and to optimize its overall diagnostic sensitivity and specificity against GEP subtypes. We divided a DLBCL cohort (n=96), where COO was defined by GEP (Lymph2CX, NanoString technologies) into training (TC, N=45) and validation cohort (VC, N=51) and tissue microarray (TMA)-TC and TMA-VC were constructed. Selected major Canadian laboratories applied their routine CD10, Bcl-6, and MUM1 IHC protocols and sent stained slides to the reference laboratory for review. The IHC protocols from laboratories were designated as "weak" (1/10), "moderate" (4/10), and "strong" (5/10) based on their overall analytical sensitivity. The results of the central review HA readouts were compared with GEP results. Furthermore, in TC, the original HA readout was modified to adjust the cutoff to overall IHC protocol sensitivity. The new readout criteria were also assessed in the VC set. The original HA readout showed good results against GEP for low sensitivity protocol only. For all other laboratories that had IHC protocols with moderate and high analytical sensitivity, a readout was adjusted to higher IHC protocol analytical sensitivity using a cutoff of >30% of >2+ staining intensity. This modification yielded significantly improved diagnostic accuracy against GEP even without any changes to the IHC protocols and was widely applicable to the range of analytical sensitivities of IHC protocols, which are currently in use. IHC biomarkers for HA can be highly accurate and harmonized across different laboratories for clinical application if the following criteria are met: (i) testing laboratories use standardized reference materials to set up and monitor analytical sensitivity, and (ii) the pathologist's readout and cutoff are adjusted to the overall IHC protocol analytical sensitivity. - Source: PubMed
Publication date: 2026/04/20
Torlakovic EminaAkhter ArizShawwa AllamMaietta AntonioOlsen BrianRoss Catherine ACheung CarolSeno H Rommel RDeschênes JeanFarinha PedroBerardi PhilipSur MonalisaAlmiski Muhamad SadekElGamal Rasha AMansoor Adnan